---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-024718"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:04:09.792738+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics Q2 BRIUMVI rev $72.6M, raises guidance; $250M credit facility; material weakness

## Summary
- Q2 BRIUMVI net revenue $72.6M (+350% YoY); net income $6.9M vs loss $47.6M.
- Raises FY 2024 BRIUMVI revenue target to ~$290-300M, up from $270-290M.
- New $250M term loan repays $107M Hercules debt; $100M share repurchase authorized.
- Material weakness in ICFR from 2021 restricted stock grant error; immaterial to financials; 10-K/A to be filed.
- Phase 1 subcutaneous ublituximab in RMS initiated; FDA IND clearance for azer-cel in progressive MS.

## SEC filing metadata
- accession: 0001437749-24-024718
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 1.02, 2.2, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000143774924024718/0001437749-24-024718-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000143774924024718/tgtx20240805_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-024718
- JSON: https://secwatch.observer/filing/0001437749-24-024718.json
- Plain text: https://secwatch.observer/filing/0001437749-24-024718.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.